Drug Profile
Research programme: sodium channel blockers - Biogen
Alternative Names: CNV 1061436; CNV-3000164; CNV-3000223; Nav 1.7 blockers - BiogenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Biogen
- Class Analgesics; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Epilepsy; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Epilepsy in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in United Kingdom (PO)
- 13 Jan 2014 Research programme: sodium channel blockers - Convergence Pharmaceuticals is available for licensing as of 13 Jan 2014. http://www.convergencepharma.com